|
T21956 |
GSK3β inhibitor II
|
|
GSK-3
|
|
GSK3β inhibitor II is a GSK3β inhibitor. GSK3β inhibitor II exhibits the research potential of Alzheimer's disease (AD). |
|
T36088 |
GSK3β Inhibitor XI
|
GSK3β Inhibitor XI |
|
|
GSK3β Inhibitor XI has GSK3β inhibitory effect. |
|
T63851 |
CDK9/10/GSK3β-IN-1
|
|
|
|
CDK9/10/GSK3β-IN-1 is a kinase inhibitor (Flavopiridol analogue) that effectively inhibits HsGSK3β, HsCDK9/CyclinT, HsCDK5/p25 and HsCDK2/CyclinA with IC50 values of 59 nM, 64 nM, 1.093 μM and 1.725 μM, respectively. CDK... |
|
T62719 |
AChE/BACE1/GSK3β-IN-1
|
|
|
|
AChE/BACE1/GSK3β-IN-1 is an orally active, blood-brain barrier-transparent, moderately bioavailable triple inhibitor of AChE/BACE1/GSK3β. AChE/BACE1/GSK3β-IN-1 can be used to study Alzheimer's disease (AD). |
|
T35556 |
GSK-3β inhibitor 8
|
GSK3β Inhibitor XVIII |
GSK-3
,
Wnt/beta-catenin
|
|
GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine derivative that negatively regulates the Wnt signaling pathway an... |
|
T35554 |
GSK-3β inhibitor 3
|
|
Apoptosis
,
GSK-3
|
|
GSK-3β inhibitor 3 is a covalent inhibitor (IC50: 6.6 μM) of glycogen synthase kinase 3β (GSK-3β) that is potent, selective, and irreversible.GSK-3β inhibitor 3 can be used to study acute promyelocytic leukemia. |
|
T39341 |
FCPR03
|
|
PDE
|
|
FCPR03 is a selective inhibitor of phosphodiesterase 4 (PDE4) with IC50s of 31 nM, 47 nM, and 60 nM for PDE4B1, PDE4D7, and PDE4 catalytic domain, respectively. FCPR03 has neuroprotective, anti-inflammatory, and antidepr... |
|
T2423 |
P7C3-A20
|
|
Others
|
|
P7C3-A20 is a derivative of P7C3 that has proneurogenic and neuroprotective activity. |
|
T22012 |
7BIO
|
|
FLT
,
DYRK
,
Aurora Kinase
|
|
7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases. |
|
T11467 |
GSK-3β inhibitor 1
|
|
GSK-3
|
|
GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy. |
|
T8376 |
PKCβ inhibitor 1
|
KUN79359 |
Apoptosis
,
PKC
|
|
PKCβ inhibitor 1 (KUN79359)(KUN79359) is a potent, selective and ATP-competitive inhibitor of PKC isozymes(IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively). |
|
T11471 |
GSK-3β inhibitor 2
|
5-Thiazolecarboxamide,2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy- |
GSK-3
|
|
|
|
T9178 |
(E/Z)-GSK-3β inhibitor 1
|
GSK-3β inhibitor 1 |
GSK-3
|
|
(E/Z)-GSK-3β inhibitor 1 is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy. |
|
T8605 |
GS87
|
4-[5-[[(3-Phenyl-1,2,4-oxadiazol-5-yl)methyl]thio]-1,3,4-oxadiazol-2-yl]pyridine |
GSK-3
|
|
GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells. |
|
T1764 |
Adezmapimod
|
PB 203580,RWJ 64809,SB203580 |
Mitophagy
,
p38 MAPK
,
Autophagy
|
|
Adezmapimod (SB 203580) is a p38 MAPK inhibitor (IC50=0.3-0.5 μM) that is selective and ATP-competitive. Adezmapimod possesses autophagy and mitochondrial autophagy activating activity. Adezmapimod displays more than 100... |
|
T1881 |
AR-A014418
|
AR 0133418,GSK-3beta Inhibitor VIII,AR 014418,GSK 3β inhibitor VIII |
GSK-3
|
|
AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor. |
|
T9025 |
KY19382
|
2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382,A3051 |
Others
,
GSK-3
,
Wnt/beta-catenin
|
|
KY19382 (2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382) is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β( IC50s of 19 and 10 nM, respectively). It... |
|
T17019 |
TCS 21311
|
NIBR3049 |
GSK-3
,
JAK
,
PKC
|
|
TCS 21311 (NIBR3049) is an effective and highly selective inhibitor of JAK3 (IC50: 8 nM). TCS 21311 inhibits PKCα, PKCθ, and GSK3β (IC50s: 13, 68, and 3 nM, respectively). It displays >100-fold selectivity over JAK1, JAK... |
|
T5200 |
Indirubin-3'-monoxime
|
Indirubin-3'-oxime |
GSK-3
,
Lipoxygenase
,
CDK
|
|
Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin B, Cdk2/cyclin E). |
|
T1830 |
BX795
|
|
IκB/IKK
,
Chk
,
CDK
,
c-Kit
,
PDK
,
Autophagy
|
|
BX795 is an effective and selective PDK1 inhibitor (IC50: 6 nM), and its selectivity is 140- and 1600-fold for PDK1 over PKA and PKC in cell-free assays, respectively. Meanwhile, the selectivity for PDK1 is 100-fold than... |
|
T5600 |
Darovasertib
|
LXS196 |
PKC
|
|
Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor(IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively). |
|
T12901 |
SHIP2-IN-1
|
|
Phosphatase
|
|
SHIP2-IN-1 is a potent SHIP2 inhibitor(IC50 : 2 µM),and used in the research of Alzheimer’s disease. |
|
T11447 |
GNF4877
|
|
GSK-3
,
DYRK
|
|
GNF4877 is a potent DYRK1A and GSK3β inhibitor (IC50s: 6 nM and 16 nM). It leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation cells. |
|
T14034 |
3CAI
|
|
Akt
|
|
|
|
T10606 |
BRD0705
|
|
GSK-3
|
|
BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM). BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50: 515 nM). |
|
T6643 |
Ro 31-8220 Mesylate
|
Ro 31-8220 methanesulfonate,Bisindolylmaleimide IX,Bisindolylmaleimide IX mesylate |
PKC
|
|
Ro 31-8220 Mesylate (Bisindolylmaleimide IX mesylate) is a pan-PKC inhibitor for PKC-α/βI/βII/γ/ε (IC50: 5/24/14/27/24 nM), and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β. |
|
T6435 |
CCT129202
|
|
Aurora Kinase
|
|
CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively. It is less potent to FGFR3, GSK3β, PDGFRβ, etc. |
|
T2052 |
KY02111
|
|
Wnt/beta-catenin
|
|
KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC. |
|
T1953 |
L-779450
|
L 779450 |
Raf
,
Autophagy
|
|
L-779450, an effective, ATP-competitive Raf kinase inhibitor (IC50: 10 nM) , displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. |
|
T66175 |
Ceftriaxone Sodium
|
|
GSK-3
,
Antibiotic
,
Aurora Kinase
|
|
Ceftriaxone Sodium is a broad-spectrum β-lactam tertiary cephalosporin antibiotic with anti-inflammatory, antitumor, antibacterial, and antioxidant activities.Ceftriaxone Sodium is a covalent GSK3β and Aurora B inhibitor... |
|
T3684 |
CP21R7
|
CP21 |
GSK-3
,
PKC
|
|
CP21R7 (CP21) is an effective and specific GSK3β inhibitor. It is used as an activator of stem cells prior to the induction of differentiation of stem cells to smooth muscle and endothelial cells. CP21R7 can be combined ... |
|
T23601 |
ABC1183
|
ABC 1183,ABC-1183 |
GSK-3
,
CDK
|
|
ABC1183 is a novel diaminothiazole that inhibits GSK3α, GSK3β and CDK9. ABC1183 inhibits the growth of a numerous cancer cell lines by decreasing cell survival by inducing G2/M arrest and through altering GSK3, glycogen ... |
|
T2506 |
AZD-5438
|
AZD5438 |
CDK
|
|
AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM). |
|
T1741 |
AZD1080
|
|
GSK-3
|
|
AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor. |
|
T12664 |
(Rac)-BRD0705
|
|
Others
|
|
(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective and orally active inhibitor of GSK3α (IC50 of 66 nM and a Kd of 4.8 μM). BRD0705 displays increased selectivity for GSK3α (8-fold... |
|
T10608 |
BRD5648
|
(R)-BRD0705 |
GSK-3
|
|
|
|
T25650 |
LDN-193665
|
LDN 193665,LDN193665 |
|
|
LDN-193665 is a potent inhibitor of tau kinase. It acts by targeting CDK5/p25 and GSK3β. |
|
T69904 |
Dihydronarwedine
|
|
|
|
Dihydronarwedine is a metabolite of Galanthamine, an inhibitor of glycogen synthase kinase 3β (GSK3β) |
|
T61578 |
BRD3731
|
|
|
|
BRD3731 is a selective inhibitor of GSK3β, demonstrating an IC50 value of 15 nM for GSK3β and 215 nM for GSK3α. Due to its inhibitory properties, BRD3731 holds promise for investigating various medical conditions, includ... |
|
T30266 |
AZD8926
|
AZD 8926,AZD-8926 |
|
|
AZD8926 is a potent and selective inhibitor of GSK3β(glycogen synthase kinase-3β). AZD8926 is potential for treating Alzheimer’s disease (AD), schizophrenia, and chronic as well as acute neurodegenerative diseases. |
|
T39457 |
(R)-BRD3731
|
(R)-BRD3731 |
|
|
(R)-BRD3731, a GSK3 inhibitor, specifically compound example 273. It exhibits inhibitory activity with respective IC50 values of 1.05 μM for GSK3β and 6.7 μM for GSK3α. |
|
T74033 |
6-Me-ATP
|
|
|
|
6-Me-ATP (N6-Methyl-ATP), a N6-modified adenosine triphosphate (ATP) derivative, exhibits strong binding affinity for glycogen synthase kinase 3 (GSK3) and acts as the phosphate group donor in GSK3β-catalyzed phosphoryla... |
|
T74034 |
6-Me-ATP trisodium
|
|
|
|
6-Me-ATP (N6-Methyl-ATP) trisodium, an N6-modified ATP derivative, demonstrates high binding affinity for GSK3 and effectively acts as the phosphate group donor in GSK3β-catalyzed phosphorylation of its substrate peptide... |
|
T3074L |
CHIR98014 HCl (252935-94-7 free base)
|
CT-98014,CHIR-98014 hydrochloride,CHIR-98014,CHIR98014 HCl,CHIR98014,CHIR 98014 |
|
|
CHIR98014 is a reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50s: 0.65 and 0.58 nM). Through its effects on GSK3, CHIR98014 stimulates glycogen synthase in cells (EC50: 106 nM), potentiates insulin-dependent... |
|
T83524 |
(rel)-Tivantinib
|
(rel)-(3R,4R)-ARQ 198,(rel)-ARQ 197 |
|
|
(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that are critical in the cellular mechanisms of non-small cell lung cancer... |
|
T40792 |
Cu(II)GTSM
|
|
|
|
Cu(II)GTSM, a cell-permeable copper-complex, effectively inhibits GSK3β and shows inhibitory effects against Amyloid-β oligomers (AβOs) while reducing tau phosphorylation. Additionally, Cu(II)GTSM decreases the abundance... |
|
T73247 |
PIM1-IN-4
|
|
Pim
|
|
PIM1-IN-4 (Compound 8) is a potent PIM1 inhibitor with significant inhibitory activity against five additional enzymes: SGK-1, PKA, CaMK-1, GSK3β, and MSK1, rendering it a potentially useful agent for cancer research [1]... |
|
T11573 |
HPN-01
|
|
Others
|
|
HPN-01 is a selective IKK inhibitor (pIC50s: 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε). HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, ErbB2, EGFR, GS... |
|
T81405 |
Presenilin 1 (349-361)
|
|
|
|
Presenilin 1 (349-361), an active peptide, is phosphorylated by glycogen synthase kinase-3β (GSK3β) in vitro when represented by its amino acid sequence 349–361. It is utilized for research into multiple diseases [1]. |
|
T83557 |
(3S,4S)-Tivantinib
|
ARQ 198,(3S,4S)-ARQ 197 |
|
|
(3S,4S)-Tivantinib, a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET, targets GSK3α and GSK3β—two novel enzymes implicated in the pathogenesis of non-small cell lung cancer (NSCLC) [1]. |
